Clinical Trials
93 trialsSTARTRK-2
Hoffmann-La Roche
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
Pfizer
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
Acerta Pharma BV
MK-6482-015
Merck Sharp & Dohme LLC
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
Janssen Research & Development, LLC
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Hoffmann-La Roche
MonumenTAL-1
Janssen Research & Development, LLC
SunRISe-1
Janssen Research & Development, LLC
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
ReNeu
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
NAVIGATE
Bayer
(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Blueprint Medicines Corporation
VISION
EMD Serono
MK-6482-004
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
MajesTEC-1
Janssen Research & Development, LLC
DPT02
AstraZeneca
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
Pfizer
Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)
Daiichi Sankyo
ZUMA-2
Gilead Sciences
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Immunocore Ltd
TROPHY U-01
Gilead Sciences
AGAVE-201
Syndax Pharmaceuticals
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Y-mAbs Therapeutics
ROSEWOOD
BeOne Medicines
NETTER-P
Advanced Accelerator Applications
A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene
Nuvation Bio Inc.
DESTINY-CRC02
Daiichi Sankyo
TRUST-II
Nuvation Bio Inc.
ZUMA-5
Gilead Sciences
DeLLphi-301
Amgen
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
Incyte Corporation
CheckMate142
Bristol-Myers Squibb
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
AbbVie
TRANSCEND FL
Celgene
ELARA
Novartis
KEYNOTE 158
Merck Sharp & Dohme LLC
HERIZON-BTC-01
Jazz Pharmaceuticals
ENESTfreedom
Novartis
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
GlaxoSmithKline
ENESTop
Novartis
A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)
Incyte Corporation
Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)
Incyte Corporation
A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
Incyte Corporation
ONC201 in Adults With Recurrent H3 K27M-mutant Glioma
Jazz Pharmaceuticals
DESTINY-Breast01
Daiichi Sankyo
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
Ipsen
DESTINY-Lung01
Daiichi Sankyo
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
Partner Therapeutics, Inc.
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
Janssen Research & Development, LLC
FIREFLY-1
Day One Biopharmaceuticals, Inc.